0.542
-0.02 (-3.71%)
| Penutupan Terdahulu | 0.563 |
| Buka | 0.545 |
| Jumlah Dagangan | 761,455 |
| Purata Dagangan (3B) | 1,748,679 |
| Modal Pasaran | 41,692,588 |
| Harga / Jualan (P/S) | 252.22 |
| Harga / Buku (P/B) | 4.42 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 Nov 2024 - 15 Nov 2024 |
| Margin Operasi (TTM) | -51,661.19% |
| EPS Cair (TTM) | -0.690 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 915.08% |
| Nisbah Semasa (MRQ) | 0.460 |
| Aliran Tunai Operasi (OCF TTM) | -30.23 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -18.18 M |
| Pulangan Atas Aset (ROA TTM) | -92.94% |
| Pulangan Atas Ekuiti (ROE TTM) | -914.66% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Eyenovia, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 2.0 |
| Purata | -0.75 |
|
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 10.00% |
| % Dimiliki oleh Institusi | 13.73% |
| Julat 52 Minggu | ||
| Median | 2.00 (268.94%) | |
| Jumlah | 1 Pegang | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 18 Nov 2024 | 2.00 (268.94%) | Pegang | 0.111 |
| 13 Nov 2024 | 12.00 (2,113.61%) | Beli | 0.408 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 06 Dec 2024 | Pengumuman | Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering |
| 25 Nov 2024 | Pengumuman | Eyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct Offering |
| 22 Nov 2024 | Pengumuman | Eyenovia Provides Update on Restructuring Efforts |
| 15 Nov 2024 | Pengumuman | Eyenovia Provides Update on Phase 3 CHAPERONE Study |
| 12 Nov 2024 | Pengumuman | Eyenovia Reports Third Quarter 2024 Financial Results and Provides Corporate Update |
| 07 Nov 2024 | Pengumuman | Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th |
| 23 Oct 2024 | Pengumuman | Eyenovia Announces Publication of Study Demonstrating Favorable Impact on the Ocular Surface of Medication Delivered with the Optejet® |
| 16 Oct 2024 | Pengumuman | Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |